STVN
Stevanato Group S.p.A.
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
22.60
▲ 0.25 (1.12%)
MARKET · —
Price
Open
22.00
Prev close
22.35
Day high
22.68
Day low
22.32
Volume
253.61K
Market cap
$6.17B
P/E (TTM)
39.65
52W range
12.89 – 28.00
Trailing performance
Returnvs SPY
1W
+7.31%
+8.7%
1M
+16.49%
+12.8%
3M
+26.61%
+23.5%
6M
+40.81%
+29.7%
YTD
+12.33%
+0.0%
1Y
-1.31%
-21.3%
3Y
-29.33%
-103.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$6.17B
Enterprise value$6.54B
Revenue (TTM)$1.23B
Gross profit$360.21M
EBITDA$298.83M
Net income$134.61M
EPS (TTM)$0.57
Free cash flow$-104.70M
Total cash$79.14M
Total debt$445.30M
Book value / share$6.57
Shares outstanding49.83M
Float49.03M
Short % of float1.84%
Dividend yield0.27%
Beta (5Y)0.74
Valuation & profitability ratios
Trailing P/E39.65
Forward P/E26.89
PEG ratio0.37
Price / sales—
Price / book3.44
EV / revenue5.34
EV / EBITDA21.88
Gross margin29.40%
Operating margin17.22%
Profit margin10.99%
Return on equity9.13%
Return on assets5.45%
Debt / equity28.73
Current ratio1.61
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $1.19B | $1.10B | $1.09B | $983.70M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $139.80M | $117.80M | $145.70M | $143.00M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $139.80M | $117.80M | $145.70M | $143.00M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.15 | 0.16 | +9.9% |
| Mar 2026 | 0.12 | 0.13 | +8.6% |
| Dec 2025 | 0.20 | 0.21 | +6.9% |
| Sep 2025 | 0.15 | 0.16 | +10.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.18 | 11 | $321.39M | +6.0% |
| Next quarter | 0.24 | 10 | $372.19M | +7.4% |
| Current year | 0.70 | 12 | $1.27B | +7.0% |
| Next year | 0.84 | 12 | $1.39B | +9.3% |
Analyst targets & ownership
Mean target$24.83
High target$32.00
Low target$20.00
Implied upside9.86%
Analyst count11
ConsensusBUY
Strong buy / Buy2 / 7
Hold3
Sell / Strong sell0 / 0
Held by insiders1.64%
Held by institutions97.14%
Institutions holding167
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+39.62K
Net buying
Buy transactions
11
53.87K shares
Sell transactions
7
14.25K shares
Net transactions
+18
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
4.48M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 7, 26 | DAL LAGO MARCO Chief Financial Officer |
SELL | 4.21K | $84.56K | Direct |
| Aug 7, 26 | MAGISTRETTI ELISABETTA Director |
SELL | 2.04K | $41.08K | Direct |
| Aug 7, 26 | SANTEL LUCIANO Director |
SELL | 2.02K | $40.64K | Direct |
| Jun 15, 26 | BALACHANDRAN MADHAVEN Director |
SELL | 1.49K | $25.52K | Direct |
| Jun 15, 26 | MOREL DONALD E JR Director |
SELL | 1.49K | $25.52K | Direct |
| Jun 15, 26 | FEDERICI WILLIAM J Director |
SELL | 1.49K | $25.52K | Direct |
| Jun 15, 26 | FLYNN KAREN A Director |
SELL | 1.49K | $25.52K | Direct |
| Jun 12, 26 | DAL LAGO MARCO Chief Financial Officer |
— | 8.00K | — | Direct |
| Jun 12, 26 | BALACHANDRAN MADHAVEN Director |
STOCK | 4.97K | $0 | Direct |
| Jun 12, 26 | MOREL DONALD E JR Director |
STOCK | 4.97K | $0 | Direct |
| Jun 12, 26 | FEDERICI WILLIAM J Director |
STOCK | 4.97K | $0 | Direct |
| Jun 12, 26 | FLYNN KAREN A Director |
STOCK | 4.97K | $0 | Direct |
| Jun 12, 26 | LIN SUE-JEAN Director |
STOCK | 4.97K | $0 | Direct |
| Jun 12, 26 | DAL LAGO MARCO Chief Financial Officer |
STOCK | 2.36K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BALACHANDRAN MADHAVEN |
Director | 69.46K | Sale |
DAL LAGO MARCO |
Chief Financial Officer | 81.14K | Sale |
FEDERICI WILLIAM J |
Director | 58.58K | Sale |
FLYNN KAREN A |
Director | 5.76K | Sale |
LIN SUE-JEAN |
Director | 6.97K | Stock Award(Grant) |
MAGISTRETTI ELISABETTA |
Director | 2.93K | Sale |
MOREL DONALD E JR |
Director | 37.42K | Sale |
SANTEL LUCIANO |
Director | 4.74K | Sale |
STOCCHI MAURO |
Officer | 413.63K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
21.46
+5.32% from price
SMA 20
20.79
+8.68% from price
SMA 50
19.40
+16.49% from price
SMA 100
18.06
+25.11% from price
SMA 200
18.43
+22.62% from price
EMA 12
21.38
+5.69% from price
EMA 26
20.64
+9.48% from price
EMA 50
19.79
+14.22% from price
RSI (14)
71.7
Overbought
MACD (12,26,9)
0.74
Hist 0.13
ATR (14)
0.73
3.24% of price
Realised vol 30D
37.0%
Annualised
Bollinger upper
22.41
20, 2σ
Bollinger lower
19.18
20, 2σ
50 / 200 cross
Golden
19.40 vs 18.43
Trend bias
Above 200
+22.62%
Risk profile
Beta vs SPY
1.20
More volatile than market
Correlation to SPY
0.32
Loosely linked
Realised vol 30D
37.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-51.4%
Peak to trough
Max drawdown 5Y
-62.2%
Peak to trough
ATR 14
0.73
3.24% of price
Beta (reported)
0.74
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.27
Call-heavy session
Put / call open interest
0.10
Positioning, not flow
Max pain
12.50
-44.7% from spot
ATM implied vol
58.2%
Nearest strike to spot
Skew (10% OTM)
+49.1%
Puts bid over calls
Call volume
26
Contracts, this expiry
Put volume
7
Contracts, this expiry
Heaviest call OI
17.50
70 contracts
Heaviest put OI
17.50
14 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Stevanato Group (STVN) Could Be 16% Undervalued Following Earnings And Guidance Update
Simply Wall St. · 12d ago
How Investors Are Reacting To Stevanato Group (STVN) Trimmed Guidance And New GLP-1 Pen Approvals
Simply Wall St. · 12d ago
Stevanato Group (STVN) Stock Looks Cheap On Cash Flow But Pricey On Earnings
Simply Wall St. · 12d ago
Stevanato Group Q2 Earnings Call Highlights
MarketBeat · 13d ago
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Zacks · 17d ago
Stevanato (STVN) Q2 2026 Earnings Call Transcript
Motley Fool · 17d ago
Stevanato Group S.p.A. Q2 2026 Earnings Call Summary
Moby · 18d ago
Stevanato Group SpA (STVN) (Q2 2026) Earnings Call Highlights: Biologics Surge and Alina ...
GuruFocus.com · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.